Fulminant Hepatic Failure in Murine Hepatitis Virus Strain 3 Infection: Tissue-Specific Expression of a Novel fgl2 Prothrombinase

J. W. DING, 1 Q. NING, 1 M. F. LIU, 1 A. LAI, 1 J. LEIBOWITZ, 2 K. M. PELTEKIAN, 3 E. H. COLE, 1 L. S. FUNG, 1 C. HOLLOWAY, 4 P. A. MARSDEN, 1, 5 H. YEGER, 6 M. JAMES PHILLIPS, 1, 6 AND GARY A. LEVY 1*

Multi-Organ Transplant Program and Departments of Medicine and Pathology, Toronto Hospital, 1 Department of Surgery, Women's College Hospital, 2 Department of Pediatric Laboratory Medicine, The Hospital for Sick Children, 3 and Department of Medicine, Division of Nephrology at St Michael's Hospital, 4 University of Toronto, Toronto, Ontario, and Department of Medicine, Dalhousie University, Halifax, Nova Scotia, 5 Canada, and Department of Pathology, Texas A & M University, College Station, Texas 6

Received 21 April 1997/Accepted 22 August 1997

Activation of the immune coagulation system has been implicated in the pathogenesis of fulminant liver failure caused by murine hepatitis virus strain 3 (MHV-3). The recent discovery of the fgl2 gene, which encodes for MHV-3-induced prothrombinase (fgl2 prothrombinase), allows for fundamental studies to determine the molecular basis for fulminant liver failure. Transcription of the fgl2 gene and translation of the protein it encodes were examined in the liver and other organs of susceptible mice following MHV-3 infection. No constitutive expression of the fgl2 gene or the fgl2 prothrombinase was detected. Within 12 to 24 h of MHV-3 infection, however, fgl2 gene transcripts were detected in large amounts in the liver, spleen, and lungs, all of which are rich in reticuloendothelial cells, but were only focally present in small amounts in the kidney and brain. There was sequential detection of fgl2 prothrombinase in the liver, where it was localized specifically to the endothelium of intrahepatic veins and hepatic sinusoids; this was allowed by fibrin deposition, which resulted in confluent hepatocellular necrosis. These results provide further evidence for the role of the selective expression of this novel fgl2 prothrombinase in the pathogenesis of MHV-3-induced fulminant liver failure.

Fibrin deposition is fundamental to pathogenesis in a number of animal models of liver injury, including that from carbon tetrachloride, endotoxin, galactosamine, acetaminophen (paraacetamol), and murine hepatitis virus strain 3 (MHV-3) (23). In the hepatocellular necrosis associated with these pathological processes, resident macrophages within the liver (Kupffer cells) exhibit morphological features of activation and release inflammatory mediators, including procoagulants, tumor necrosis factor alpha (TNF-α), interleukin-1 (IL-1), proteolytic enzymes, and eicosanoids as well as superoxide anions and nitric oxide (12).

Studies from this laboratory have demonstrated a pivotal role for a procoagulant with prothrombin-cleaving activity (prothrombinase) in MHV-3-induced hepatic necrosis. Macrophages isolated from susceptible (BALB/c) but not from resistant (A/J) animals express large amounts of this prothrombinase in vitro and in vivo. Of great interest is that systemic inhibition of the prothrombinase with high-titer neutralizing monoclonal antibody prevents hepatic necrosis and prolongs survival in MHV-3-susceptible mice (15). These observations define a unique interface between immune-mediated coagulation and the acute inflammatory disease fulminant hepatitis. Recently, this laboratory reported the isolation and functional expression of complementary DNA clones for this prothrombinase, termed fgl2 (20). The molecular clone corresponded to a mouse fibrinogen-like protein (7, 10). Examination of the predicted protein structure showed 36% sequence similarity with the C-terminal portion of the beta and gamma subunits of fibrinogen, similar to other members of the fibrinogen family of proteins (10). When the entire coding region was expressed by a coupled vaccinia virus-bacteriophage system in RAW 264.7 cells, a marked expression of prothrombinase activity was observed (20). Therefore, the gene fgl2 encoded a specific prothrombinase involved in the pathogenesis of MHV-3 infection. The murine gene for the fgl2 prothrombinase was localized to proximal regions of mouse chromosome 5 (20, 25). We and others have shown that MHV-3 replicates in many tissues, including lung, bowel, brain, kidney, and spleen, in addition to the liver, and yet disease as defined by fibrin deposition and cellular necrosis is confined to the liver (11, 16). The present study demonstrates that following MHV-3 infection of susceptible BALB/c mice, fgl2 mRNA transcripts are strongly induced in macrophage-rich organs, such as the liver, spleen, and lungs; however, immunoreactive fgl2 (fgl2 prothrombinase) was expressed only in the liver. Furthermore, both fgl2 mRNA transcripts and fgl2 prothrombinase were expressed only by Kupffer cells and endothelial cells and not by hepatocytes of the liver after MHV-3 infection. The expression of the fgl2 prothrombinase was promptly followed by fibrin deposition and massive hepatic necrosis, hallmarks of fulminant liver disease.

MATERIALS AND METHODS

Mice. Female BALB/c mice, 8 weeks of age, were purchased from Jackson Laboratory (Bar Harbor, Maine), and were housed in the animal facility at the Toronto Hospital Research Institute, University of Toronto. Mice were kept in a controlled-temperature (22°C) environment with 12-h light-dark cycles and were given access to standard chow (LabDiet; PMI Feeds, Inc., St. Louis, Mo.) and water ad libitum prior to and during the experiment. Animals acclimatized to laboratory conditions for 1 week prior to experiments and were handled strictly according to Guide to the Care and Use of Experimental Animals of the Canadian Council on Animal Care.
Reagents. The reagents used in the experiments included RPMI 1640, guani- 
dine isothiocyanate, guanidine hydrochloride, redistilled formamide, ethidium 
bromide, and Hanks’ balanced salt solution (HBSS) (GIBCO BRL, Life 
Technologies, Grand Island, N.Y.); DNA grade agarose (Bio-Rad, Laboratories, 
Herlev, Denmark); 50% glycerol; thioglycolate (Difco Laboratories, 
Detroit, Mich.); collagenase B and DNaSe I (Boehringer Mannheim, Quebec, 
Canada); pronase (Calbiochem, La Jolla, Calif.); fetal calf serum (FCS) (Flow 
Laboratories, Mississauga, Ontario, Canada); and [α-32P]dCTP (3,000 Ci/mmol) 
(Amersham, Oakville, Ontario, Canada).

Viruses. MTC stock was plaque purified on monolayers of DBT cells and was grown to a titer of 1×10^10 PFU per ml in 17 CL1 cells. Viral titers were determined on monolayers of L2 cells by a standard plaque assay as described elsewhere (11, 16).

Organ collection. The livers, spleens, lungs, kidneys, and brains were removed from BALB/c mice at 2, 4, 6, 8, 16, 24, 36, and 48 h after intraperitoneal administration of MHV-3 (10^5 PFU/mouse); organs removed immediately after MHV-3 infection (0 h) were used as normal controls. The organs were embedded in a cryoprotectant (O.C.T. compound; Miles Inc., Elkhart, Ind.) in cryomolds and snap frozen in liquid nitrogen. The organs were removed 24 h after MHV-3 infection were fixed in 4% paraformaldehyde at room temperature. The fixed tissue blocks were then embedded in paraffin and sectioned. The frozen organs were kept at −20°C. Total RNA was pelleted by centrifugation at 14,000 rpm at 4°C for 30 min (Eppendorf centrifuge 5402; Netheler-Hinz GmbH, Hamburg, Germany). Briefly, macrophages were lysed in 8 M guanidine hydrochloride and sheared total RNA was extracted as described previously (5) with minor modifications. Total cellular RNA from 1×10^6/ml in RPMI 1640 containing 2 mM glutamine. Macrophages represented a 10% homogenate at 4°C, and titers were then determined on L2 cell monolayers by a standard plaque assay as described previously (11, 16).

Peritoneal macrophages. Peritoneal macrophages from BALB/c mice were harvested 4 days after intraperitoneal injection of 1.5 ml of 3% thioglycolate as described previously (13). Macrophages were resuspended at a concentration of 10^5/ml in RPMI 1640 containing 2 mM glutamate. Macrophages represented a homogeneous population greater than 95% in purity as determined by morphol- ogy, nonspecific esterase staining, and staining with Mac-1 antibody (4).

Extraction of total RNA from macrophages. Peritoneal macrophages were infected with MHV-3 (multiplicity of infection = 5) and washed free of virus, and total RNA was extracted as described previously (5) with minor modifications. Briefly, the macrophage monolayers were homogenized in 2 M sodium acetate at 4°C and then dialyzed against 200 volumes of 50 mM Tris (pH 7.5) and 1 M NaCl, 10 mM NaH_{2}PO_{4}, and 1 mM EDTA (pH 7.9)–5% Denhardt’s solution–0.5% SDS–100 µg of denatured salmon sperm DNA per ml at 42°C for 18 h with [α-32P]dCTP-labeled 1.2-kb DNA probe of murine fgf2 cDNA (7 × 10^6 cpm/ 
µl; 300,000 cpm/10 µl). The homogenate was then mixed with 2 M sodium acetate, 0.1 M 2-mercaptoethanol, and 0.5% N-lauroylsarcosine.

In situ hybridization. In situ hybridization. The method used here has been described previously (31). Digoxigenin-11-UTP (Dig-UTP) (Boehringer Mannheim, Quebec, Cana-
da) labeled DNA probes (antisense and sense) were synthesized with T7 and T3 RNA polymerases following subcloning of a 650-bp fragment of fgf2 cDNA, representing nucleotides 846 (TGTGACACTG . . .) to 1495 (. . .AGTAACAGT) (20), into the EcoRI site of plueScript (Stratagene, La Jolla, Calif.). The Dig-UTP-labeled probe concentration was determined by immunoenzymatic reaction with chemiluminescent detection, and the probes were stored at −80°C. Tissue sec-
tions were deparaffinized in 100% xylene and 100% alcohol, followed by prehy-
bridization in 50% formamide and 2× SSC at room temperature for 1 h. The hybridization mixture consisted of 50% deionized formamide, 5% dextran sul-
fate, 250 µg of salmon sperm DNA per ml, and 2 µg of Dig-labeled RNA probe per 
ml in 2× SSC. The hybridization mixture with the probe was denatured by 
heating in an 85°C water bath for 5 min, chilled on ice for 1 min, and added to 
tissue sections. Sections were overlaid with an equal volume of hybridization 
medium. Filters were then incubated with the hybridization solution for a 
series of dilutions of SSC was followed by application of 3% blocking reagent 
at room temperature for 30 min. After a brief wash in Tris-HCl buffer (pH 7.5), 
sections were incubated with polyclonal anti-Dig Fab fragments (1:50 dilution), 
diluted in 1× SSC, at 37°C for 1 h. Unbound antibody was removed by two 5-min washes with Tris-HCl buffer. A purple reaction product developed when alkaline phosphatase conjugated to rabbit IgG (Cappel Laboratories, Durham, N.C.) was used to detect the alkaline phosphatase activity. Sections were counterstained with methylgreen and mounted in Permount for viewing.

Immunohistochemical staining. (i) Immunofluorescence for detection of the fgf2 prohormone. In order to determine whether fgf2 prohormone immu-
noreactivity was expressed in the organs where fgf2 mRNA transcripts were 
evident following MHV-3 infection, immunohistochemical staining of various 
organs was performed with a rabbit polyclonal antibody made against the fgf2 prohormone. Snap-frozen tissue specimens were cryosectioned at 6-µm thick-
ness and mounted on glass slides. Tissue slices were fixed with 100% methanol at 4°C for 5 min and air dried. They were rehydrated with 0.1 M PBS (pH 7.4) 
and blocked with 10% normal horse serum in PBS at room temperature for 2 h. An affinity-purified polyclonal antibody to the murine fgf2 prohormone was produced in rabbits by repeated injections with a 14-amino-acid hydrophilic 
peptide (CKLQADDHRDPGGN) from exon 1 of the fgf2 prohormone which had 
been coupled to keyhole limpet hemocyanin. Tissue slices were first incu-
bated with antibody (30 µg/ml in PBS) at room temperature for 2 h and then 
incubated with fluorescein isothiocyanate-conjugated goat immunoglobulin G 
(IgG) (6.7 µg/ml) fraction to rabbit IgG Fc (Cappel Laboratories, Durham, N.C.) at 
temperature for 1 h, following which they were washed five times in PBS 
with 0.05% Tween 20. Tissue slices were then air dried, mounted with 90% glycerol, and photographed on a Zeiss Laborlux fluorescence S microscope (Ernst Leitz Wetzlar GmbH, Wetzlar, Germany).

(ii) Immunoperoxidase staining of fibrin. Liver tissue from BALB/c mice 
between 0 to 48 h after MHV-3 infection was examined for the presence of fibrin. The primary antigen was a monoclonal antibody against pro-
fibrinogen, a purified immunoglobulin fraction of rabbit antiserum (DAKO, Carpinte-
ria, Calif.) labeled with 125I-goat anti-mouse IgG (6.7 µg/ml) fraction to rabbit IgG Fc (Cappel Laboratories, Durham, N.C.). Tissue sections were incu-
bated with primary antibody (IgG) at room temperature for 2 h, washed, and then 
incubated with 1:50 dilution of IgG-peroxidase (Cappel Laboratories, Durham, N.C.) for 1 h. Tissue sections were then washed 3× with Tris-HCl buffer, followed by a brief wash in PBS containing 0.02% hydrogen peroxide and 0.3% 
hydrogen peroxide. They were then incubated for 30 min with 3,3′-diaminobenzidine 
(DAB) as a chromogen. Sections were then washed 3× in Tris-HCl buffer, followed by a 5-min incubation in 100% methanol. Sections were counterstained with methylgreen and mounted in Permount for viewing.
ria, Calif.). The antibody is known to react with native human fibrinogen as well as with the fibrinogens of other species and with fibrin in human tissues and in the mouse. The technique utilized for detection of fibrin was the standard avidin-biotin complex method. The biotinylated secondary antibody was anti-rabbit IgG linked to peroxidase reacted with 3,3'-diaminobenzidine chromagen, followed by counterstaining with hematoxylin. Serial sections were stained with hematoxylin and eosin.

**Statistical analysis.** Quantitative data were expressed as means ± standard deviations. Statistical analysis was carried out by using one-way analysis of variance, and a $P$ value of less than 0.05 was considered statistically significant.

**RESULTS**

**Histology.** Tissues, including liver, spleen, lungs, kidneys, and brain, from mice after MHV-3 infection were examined as described above. Histopathological changes were found only in the liver and not in the other organs examined. At 24 h postinfection, numerous small, discrete nonzonal foci of necrosis with a sparse polymorphonuclear leukocyte infiltrate could be seen in livers from BALB/c mice. At 48 h, these lesions became larger, more numerous, and frequently panlobular, and there was early confluent necrosis (Fig. 1). Fibrin deposition was present but was difficult to recognize (see Fig. 7).

**Viral titers in the organs after MHV-3 infection.** High titers of virus were found in all tissues examined. The viral titers in the liver detected 24 h following MHV-3 infection were significantly higher than those in the lungs, kidneys, and brain ($P < 0.001$), but there was no difference in viral titers between liver and spleen ($P > 0.05$) (Fig. 2).

**Effect of MHV-3 on steady-state $fgl2$ mRNA transcripts in murine tissues.** Northern blot analysis of total cellular RNAs extracted from uninfected and infected organs at various time points after intraperitoneal administration of MHV-3 is shown in Fig. 3. The mRNA for $fgl2$ was not constitutively expressed in the tissues examined in this study. In the liver, $fgl2$ mRNA transcripts were detected at 8 h and persisted to 48 h, the last time point studied, after MHV-3 infection (Fig. 3A). Similarly, mRNA transcripts for $fgl2$ were first detected at 6 h in the spleen (Fig. 3B) and lungs (Fig. 3C) and persisted for 48 h after MHV-3 infection. In these organs the mRNA transcripts were localized to macrophages and endothelial cells. Despite the presence of mRNA transcripts in the spleen, no $fgl2$ prothrombinase (protein) was detected even at day 5, just prior to death of the animals. After 48 h, transcripts (mRNA) were not seen in these tissues. By Northern blot analysis, no constitutive or

**FIG. 1.** BALB/c mouse liver at 48 h after MHV-3 infection. Confluent hepatocellular necrosis of liver parenchyma is shown (+). Necrotic cells show nuclear karyorrhexis, loss of cell membranes, and granular disintegration of cell cytoplasm. Fibrin is present as thin strands in the sinusoids (arrowheads). The nonnecrotic hepatocytes appear histologically normal. Hematoxylin-and-eosin stain was used. Magnification, ×300.

**FIG. 2.** Determination of viral titers in organs at 24 h following MHV-3 infection. The viral titer in the liver was significantly higher than those in the lung, kidney, and brain ($P < 0.001$) but did not differ significantly from that in the spleen ($P > 0.05$). Error bars indicate standard deviations.
cDNA was used to ensure equal levels of mRNA in all lanes (data not shown). In the kidney, fgl2 transcripts were found in subcortical neurons, and in the kidney, the fgl2 transcripts were confined to the tubular epithelium of the inner medulla.

**Immunohistochemical staining.** Immunohistochemical staining of the liver for fgl2 prothrombinase showed that it was not evident in normal controls (Fig. 6A) but was present only in the liver following MHV-3 infection, where it was first localized at 24 h postinfection to the sinusoids and large veins (Fig. 6B), but by 48 h it was seen in sinusoids and large confluent areas of hepatocellular necrosis (Fig. 6C). fgl2 prothrombinase increased until day 5, when the animals died. fgl2 immunoreactivity was not detected in any other organs, including the spleen, lungs, kidneys, and brain, either constitutively or following MHV-3 infection (data not shown).

Sections of livers from BALB/c mice examined at the onset of the experiments showed normal histology, and all were negative for fibrin. At 24 h after infection, the livers of BALB/c mice showed fibrin deposits in hepatic sinusoids; the deposits were randomly distributed as discrete microfoci throughout the liver. Occasionally, branches of intrahepatic veins also showed fibrin deposits. Hepatocytes appeared to be completely normal, except in widely scattered focal areas where liver cell necrosis was seen. In all instances, the necrosis was confined to areas where the fibrin deposits were most extensive and involved contiguous sinusoids. The necrotic hepatocytes showed complete karyorrhexis of nuclei, loss of cell membranes, and granular disintegration of cell structure, but hepatocytes elsewhere were normal. At 36 h these changes had progressed, and the focal fibrin deposits and focal necrosis pattern had changed to confluent areas of bridging necrosis and panlobular necrosis. By 48 h, widespread multifocal areas of fibrin deposition and hepatocellular necrosis were evident, involving approximately 50% of the liver parenchyma. In every instance, the necrosis was associated with extensive fibrin deposits. No hepatocellular necrosis was seen in areas without fibrin deposition. The parenchyma in nonnecrotic areas still looked normal histologically. These studies showed a clear-cut progression of histopathological changes, beginning with discrete deposits of fibrin in sinusoids and progressing to larger areas of fibrin deposition accompanied by discrete foci of hepatocellular necrosis and finally to areas of confluent hepatic necrosis. In the larger areas of necrosis, fibrin was present throughout the lesions, and in some of them, neutrophils were present as well (Fig. 1 and 7).
DISCUSSION

The recent molecular characterization of the fgl2 prothrombinase now allows for definitive studies to determine the cellular mechanisms involved in the pathogenesis of MHV-3-induced fulminant hepatic failure. Within 8 h of MHV-3 infection, mRNA transcripts for the murine fgl2 gene were evident in reticuloendothelial cells of the liver. Within 12 to 24 h MHV-3 infection, expression of the novel fgl2 prothrombinase immunoreactivity was detected in liver tissue from susceptible MHV-3-infected mice. The fgl2 prothrombinase was seen in endothelial cells lining large veins, in the hepatic sinusoids, and in areas of focal necrosis. Shortly thereafter, and within 24 h, focal deposits of fibrin were found in the liver sinusoids. By 48 h, the fibrin deposits were extensive and were accompanied by multifocal confluent hepatocellular necrosis. By Northern blot analysis and in situ hybridization fgl2 mRNA transcripts were detected in other organs, no translation product (fgl2 prothrombinase) or disease was seen outside the liver despite the presence of high viral titers. Supportive of this observation was the fact that functional prothrombinase activity was seen only in the liver at 18 hours, increasing to 72 h and remaining stable at high levels until day 5, the time of death, whereas no such activity was seen in the lung or spleen at any time point.

MHV can produce a broad spectrum of diseases, including pneumonitis, encephalitis, enterocolitis, nephritis, and hepatitis (30). Although the virus replicates in all tissues, disease is not seen in tissues in which high viral titers are recovered, and the pattern of disease is organ specific. Data from our and other laboratories have suggested that host factors may be more critical than viral replication in the pathogenesis of MHV diseases (8, 23, 32). Although in this and previous studies, replication of MHV-3 was significantly different in each organ examined, only in the liver is histopathology seen following MHV-3 infection. Thus, the fact that we saw large differences in viral replication in tissues in this study following MHV-3 infection was not unexpected and was consistent with other reports (8). Furthermore, the observation that the spleen and lungs were anatomically normal yet had high viral titers similar to those found in the liver supports the concept that viral replication alone will not explain MHV-3 disease.

Fibrin deposition in the liver is a unique feature of MHV-3-induced fulminant liver failure, whereas infection of the brain with MHV-JAM results primarily in demyelination with no associated fibrin deposition (3, 6, 8). Thus, the detection of mRNA transcripts in the lung, kidney, and brain following MHV-3 infection suggests that this gene may be involved in other MHV diseases. The short time course of MHV-3-induced fulminant hepatic necrosis may preclude development of disease in these organs.

It is well documented that MHV-3 disease is localized to the liver and that other organs are relatively spared (22). The fact that no fgl2 prothrombinase was detected outside the liver was expected and was consistent with our hypothesis of the importance of this molecule in the MHV-3-induced liver disease. At this time, we cannot fully explain why translation of the fgl2 gene does not occur in extrahepatic tissues, but this may reflect differences in rates of mRNA transcription, mRNA stabilities in different organs, and/or molecules that interfere with translation of the gene. These findings are consistent with our previous study in which mRNA transcripts for fgl2 were evident in macrophages and liver tissue of resistant A/J mice following MHV-3 infection (20). However, in this MHV-3-resistant strain, no fgl2 immunoreactive prothrombinase or liver disease was seen (20).

Although by the molecular techniques employed it appears
that there are fewer steady-state \(fgl2\) mRNA transcripts in the liver than in other organs, this likely reflects the fact that no \(fgl2\) mRNA transcripts are expressed either constitutively or following MHV-3 infection in hepatocytes, which constitute the major cell type of the liver. Northern analysis of subfractionated cells from the liver demonstrated high levels of \(fgl2\) mRNA transcripts only in reticuloendothelial cells of the liver. Our observations are consistent with previous studies showing that the first abnormalities in the liver following MHV-3 infection, as observed by dynamic intravital microscopy, are disturbances of the liver microcirculation associated with sinusoidal microthrombosis (16). At no time was liver necrosis seen in the absence of fibrin. Thus, these findings firmly establish the importance of induction of the \(fgl2\) prothrombinase encoded by the \(fgl2\) gene in the pathogenesis of hepatocellular necrosis.

Our previous studies demonstrated that MHV-3 infection of macrophages resulted in transcription of a number of host inflammatory cytokines, including TNF-\(\alpha\), IL-1, and superoxides (23). Cytokines can play a potent role in the course of inflammatory injury in vivo, and interference with their action can alter the courses of certain inflammatory diseases (28, 29). Treatment of rats with recombinant antibody to TNF has been shown to protect animals from hypotension, hypothermia, and mortality of gram-negative sepsis (21), and treatment of rabbits with an IL-1 receptor antagonist reduced mortality associated with endotoxin shock (2, 19). We have now shown that both IL-1 and TNF-\(\alpha\) directly induce endothelial cell transcription of \(fgl2\) (20). The importance of the \(fgl2\) prothrombinase in the pathogenesis of MHV-3 infection is further supported by the observation that a neutralizing antibody to this protein prevents fibrin deposition and protects mice from the lethality of MHV-3 infection (15).

The importance of the immune coagulation system resulting in fibrin deposition in human fulminant liver failure is controversial (14). Mori et al. have reported that fibrin is a classical feature of fulminant hepatitis (17, 18), but this has not been substantiated by others (24, 33). The reason for not finding fibrin in tissue sections may rest with the methodologies used. In routine hematoxylin-and-eosin-stained sections, fibrin is not easily recognized, and its presence is further obscured by hepatic necrosis. Even the use of special stains for fibrin is not always conclusive in our experience. However, by using recently available specific antibodies such as those used in this study, fibrin is clearly evident in the hepatic lesions of MHV-3-infected livers from susceptible mice. Because of these observations with MHV-3-infected mice, we have now reexamined liver tissue from patients with fulminant liver failure and have found fibrin deposits by using methodologies similar to those described in this report (unpublished data).

In conclusion, \(fgl2\) mRNA transcripts are seen in reticuloendothelial cell-rich organs, including liver, spleen, and lungs, following MHV-3 infection. However, \(fgl2\) prothrombinase immunoreactivity is evident only in the liver. The induction of this
protein in the sinusoids and large portal veins initiates micro-
thrombosis and fibrin deposition, which lead to perturbations in
microvascular hemodynamics and subsequent liver cell nec-
rosis. These studies firmly establish the pivotal role of fgf2 and its
protein product in the pathogenesis of fulminant liver fail-
ure caused by MHV-3.

ACKNOWLEDGMENTS

This work was supported by group grant PG 11810 from the Medical
Research Council of Canada.

We are grateful to Charmaine Beal and Dawn Paluch for excellent
secretarial assistance.

REFERENCES

   Levy. 1987. 16,16-Dimethyl prostaglandin E2 prevents the development of
   fulminant hepatitis and blocks the induction of monocyte/macrophage pro-
   Invest. 80:881–889.

2. Alexander, J. R., B. C. Sheppard, J. C. Jensen, H. Langstein, C. M. Buresh,
   1987. Treatment with recombinant human tumor necrosis factor-alpha pro-
   tects rats against the lethality, hypotension and hypothermia of gram-nega-

   Mouse hepatitis virus 4 (MHV-JHM) induced neurological disease is mod-

   mice with the JAM strain of mouse hepatitis virus alters in-vitro splenic T

5. Evans, R., and S. J. Kamdar. 1990. Stability of RNA isolated from macro-
   phages depends on the removal of an RNA-degrading activity early in the

   1989. Monoclonal antibodies to the matrix (E1) glycoprotein of mouse hep-

   Levy. 1991. Monoclonal antibody analysis of a unique macrophage proco-
   agulant activity induced by murine hepatitis virus strain 3 infection. J. Biol.
   Chem. 266:1789–1795.


    Structure of a cytotoxic T-lymphocyte-specific gene shows a strong homology to


    Dis. 10:293–304.

    monocyte procoagulant activity by murine hepatitis virus MHV-3 parallels

    hepatitis and immunologic activity of the coagulation protease network.
    Semin. Liver Dis. 4:59–68.

15. Li, C., L. S. Fung, A. Crow, N. Myers-Mason, M. J. Phillips, J. L. Leibowitz,
    nase (3D4.3) prevents mortality from murine hepatitis virus (MHV-3) infec-

    69:5033–5038.

17. Mori, W., and A. Naoto. 1981. Acute hepatic cell necrosis experimentally

18. Mori, W., J. Shiga, and H. Irie. 1986. Schwartzman reaction as a pathoge-

    1990. Interleukin-1 receptor antagonist reduces mortality from endotoxin

    Levy. 1995. Association of mouse fibrinogen-like protein with murine hep-

21. Patton, J. S., P. M. Peters, J. McCable, D. Crase, S. Hansen, A. B. Chen, and
    D. Liggett. 1987. Development of partial tolerance to the gastrointestinal
    effects of high doses of recombinant tumor necrosis factor-alpha in rodents.

    Springfield, Ill.

    Pattern of disease after murine hepatitis virus strain 3 infection correlates

    and R. Williams. 1975. Histopathological changes in the liver following a
    paracetamol overdose: correlation with clinical and biochemical parameters.

    Mouse hepatitis virus-3 induced procoagulant (Fg12) maps to proximal

    and W. Strober (ed.). Current protocols in immunology, supplement 3. John
    Wiley & Sons, Inc., New York, N.Y.


    and tissue injury induced by recombinant human cachectin. Science 234:470–
    474.

29. Tracey, K. J., S. F. Lowry, T. J. Fahey, J. D. Albert, Y. Fong, D. Hesse, B.
    necrosis factor induces lethal shock and stress hormone responses in the dog.


ERRATA

Attenuated Replication of Human Immunodeficiency Virus Type 1 with a Didanosine-Selected Reverse Transcriptase Mutation
PREM L. SHARMA AND CLYDE S. CRUMPACKER
Division of Infectious Disease, Beth Israel Deaconess Medical Center, and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215

Volume 71, no. 11, p. 8850: Add the following sentence to the Acknowledgments: “Additional support was provided by NIH grants AI27659 and AI38858 and by training grant ST32 AI07387.”

Fulminant Hepatic Failure in Murine Hepatitis Virus Strain 3 Infection: Tissue-Specific Expression of a Novel fgl2 Prothrombinase
Multi-Organ Transplant Program and Departments of Medicine and Pathology, Toronto Hospital, Department of Surgery, Women’s College Hospital, Department of Pediatric Laboratory Medicine, The Hospital for Sick Children, and Department of Medicine, Division of Nephrology at St Michael’s Hospital, University of Toronto, Toronto, Ontario, and Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada, and Department of Pathology, Texas A & M University, College Station, Texas

Volume 71, no. 12, p. 9225 and 9229: Figures 1 and 7 were transposed; the legends are correct.